id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2026-N-10165-0002,FDA,FDA-2026-N-10165,CBER-CDER Pre-Read,Supporting & Related Material,Background Material,2026-09-16T04:00:00Z,2026,9,,,2026-09-16T20:28:17Z,,0,0,09000064b957117c
FDA-2026-N-10165-0003,FDA,FDA-2026-N-10165,CDRH Pre-Read,Supporting & Related Material,Background Material,2026-09-16T04:00:00Z,2026,9,,,2026-09-16T20:28:32Z,,0,0,09000064b957117d
FDA-2026-N-10165-0001,FDA,FDA-2026-N-10165,Statistical Considerations for the Design of Rare Disease Clinical Investigations; Establishment of a Public Docket; Request for Information and Comments,Notice,Request for Comments,2026-09-15T04:00:00Z,2026,9,2026-09-15T04:00:00Z,2026-11-14T04:59:59Z,2026-09-16T09:00:44Z,2026-18805,1,0,09000064b955afbc